These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 25622075)

  • 21. Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
    Kim MN; Ro SW; Kim DY; Kim da Y; Cho KJ; Park JH; Lim HY; Han KH
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):257-67. PubMed ID: 26037205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Questiomycin A stimulates sorafenib-induced cell death via suppression of glucose-regulated protein 78.
    Machihara K; Tanaka H; Hayashi Y; Murakami I; Namba T
    Biochem Biophys Res Commun; 2017 Oct; 492(1):33-40. PubMed ID: 28811106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.
    Liu Y; Lou G; Norton JT; Wang C; Kandela I; Tang S; Shank NI; Gupta P; Huang M; Avram MJ; Green R; Mazar A; Appella D; Chen Z; Huang S
    FASEB J; 2017 Dec; 31(12):5453-5465. PubMed ID: 28821631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
    Tang TC; Man S; Lee CR; Xu P; Kerbel RS
    Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling.
    Zhang SS; Ni YH; Zhao CR; Qiao Z; Yu HX; Wang LY; Sun JY; Du C; Zhang JH; Dong LY; Wang K; Gao JJ
    Acta Pharmacol Sin; 2018 Mar; 39(3):438-448. PubMed ID: 29188798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
    Cui T; Zhang S; Sun H
    Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual-Targeting Nanoparticles: Codelivery of Curcumin and 5-Fluorouracil for Synergistic Treatment of Hepatocarcinoma.
    Ni W; Li Z; Liu Z; Ji Y; Wu L; Sun S; Jian X; Gao X
    J Pharm Sci; 2019 Mar; 108(3):1284-1295. PubMed ID: 30395829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma
    Tsai JJ; Hsu FT; Pan PJ; Chen CW; Kuo YC
    Anticancer Res; 2018 Apr; 38(4):2119-2125. PubMed ID: 29599330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
    Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
    Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
    Zhang L; Gong F; Zhang F; Ma J; Zhang P; Shen J
    Int J Nanomedicine; 2013; 8():1517-24. PubMed ID: 23620667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
    BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.
    Fernando J; Malfettone A; Cepeda EB; Vilarrasa-Blasi R; Bertran E; Raimondi G; Fabra À; Alvarez-Barrientos A; Fernández-Salguero P; Fernández-Rodríguez CM; Giannelli G; Sancho P; Fabregat I
    Int J Cancer; 2015 Feb; 136(4):E161-72. PubMed ID: 25053293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
    Chen C; Ju R; Shi J; Chen W; Sun F; Zhu L; Li J; Zhang D; Ye C; Guo L
    J Pharmacol Exp Ther; 2017 Aug; 362(2):219-229. PubMed ID: 28515157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
    Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
    Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
    Schmithals C; Köberle V; Korkusuz H; Pleli T; Kakoschky B; Augusto EA; Ibrahim AA; Arencibia JM; Vafaizadeh V; Groner B; Korf HW; Kronenberger B; Zeuzem S; Vogl TJ; Waidmann O; Piiper A
    Cancer Res; 2015 Aug; 75(15):3147-54. PubMed ID: 26239478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H; Zhang C; Chi H; Meng Z
    Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma.
    Thapa RK; Choi JY; Poudel BK; Hiep TT; Pathak S; Gupta B; Choi HG; Yong CS; Kim JO
    ACS Appl Mater Interfaces; 2015 Sep; 7(36):20360-8. PubMed ID: 26315487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma.
    Malarvizhi GL; Retnakumari AP; Nair S; Koyakutty M
    Nanomedicine; 2014 Nov; 10(8):1649-59. PubMed ID: 24905399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequence‑dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action.
    Bahman AA; Abaza MSI; Khoushiash SI; Al-Attiyah RJ
    Int J Mol Med; 2018 Sep; 42(3):1695-1715. PubMed ID: 29901131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
    Grillone A; Riva ER; Mondini A; Forte C; Calucci L; Innocenti C; de Julian Fernandez C; Cappello V; Gemmi M; Moscato S; Ronca F; Sacco R; Mattoli V; Ciofani G
    Adv Healthc Mater; 2015 Aug; 4(11):1681-90. PubMed ID: 26039933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.